Abstract: Objective 　To study the relationship of therapeutic method of PEIT (percutaneous ethanol in2 jection for therapy, PEIT) and T2cell changing of advanced liver cancer, and observe the clinical effect . Methods 　Applying APAAP method, we tested the CD4 + and CD8 + T2cell changing when the advanced liver cancer patient s t reated by PEIT and detected the tumor size changing by B2ult rasound and CT, and observed the prognosis at the same time. Results 　The CD4 + T2cell, CD4 + / CD8 + was reduced signifi2 cantly in the advanced liver cancer patient s than that of the normal cont rol group, the CD4 + T2cell, CD4 + / CD8 + was adjusted to normal cevel af ter had been t reated by PEIT. The CD4 + T2cell, CD4 + /CD8 + was also reduced significantly in metastatic liver cancer patient s than that of the normal cont rol group, the CD8 + was high especially. The CD4 + T2cell, CD4 + / CD8 + was also been adjusted to normal level after had been t reated by PEIT. Metastatic liver cancer patient s could tolerant to PEIT than the liv2 er cancer patient s. The over2all survival could be prolonged when the patient s t reated by PEIT. Conclu2 sion 　The patient of advanced liver cancer is hypoimmunity, and it can be adjusted to normal level when t reated by PEIT. PEIT is a useful therapeutic method for advanced liver cancer patient we can choose.